Drug Discovery Biotechnology Company
We are an emerging biotechnology company dedicated to the discovery of small-molecule therapeutics and diagnostics for the treatment of the debilitating neurological orphan indication of amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). We incorporate modern aspects of drug discovery including compound library synthesis and screening. In partnership with top academic and industrial laboratories, ALS Biopharma, LLC is researching both small molecule and biologic protein-based approaches to treat the disease.
Location and Facilities
We are located in the Pennsylvania Center for Drug Discovery at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA (www.pabiotechbc.org).
Our laboratories at the PBC include a complete array of chemistry and biochemistry tools and equipment such as a real time PCR, laminar flow hoods, table top centrifuges, Thermofinnagan LCQ and ABI Qtrap Mass Specs, Waters HPLC systems, a Biomek robot liquid handler, and other equipment that is routine for modern molecular biology, high throughput screening, and medicinal chemistry.
Recent Publications
Pawlyk, A. C.; Cassel, J. A.; Reitz, A. B. Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis. Curr. Pharm. Des. 2010, 16, 2053.
Cassel, J. A.; Blass, B. E.; Reitz, A. B.; Pawlyk, A. C. Development of a Nonradiometric Assay for Nucleic Acid Binding to TDP-43 Suitable for High-Throughput Screening Using AlphaScreen® Technology. J. Biomolecular Screening, 2010, 15, 1099-1106:
Press Releases and News
